BTG1 Antibody

1. This study demonstrated for the first time that lower expression of BTG1 correlated with poor survival in PDAC patients, which suggests that BTG1 expression may serve as an available prognostic biomarker in the future PMID:29076521
2. BTG1 expression is lowered in colorectal cancer cells. Forced BTG1 expression reverses aggressive phenotypes in colorectal cancers. PMID:27447746
3. BTG1 down-regulation in colorectal cancer occurs through epigenetic repression, which is involved in the development and progression of colorectal cancer. PMID:29374692
4. BTG1 gene deletion is associated with acute lymphoblastic leukemia. PMID:28033648
5. our results identify BTG1 as a tumor suppressor in leukemia that, when deleted, strongly enhances the risk of relapse in IKZF1-deleted B-cell precursor acute lymphoblastic leukemia, and augments the glucocorticoid resistance phenotype mediated by the loss of IKZF1 function. PMID:27979924
6. BTG1 interacts with ATF4 and positively modulates its activity by recruiting the protein arginine methyl transferase PRMT1 to methylate ATF4 on arginine residue 239. PMID:26657730
7. our data suggest that BTG1 overexpression combined with radiation therapy increases the therapeutic efficacy of breast cancer treatment via regulation of the cell cycle and apoptosis-related signaling pathways. PMID:26503430
8. Suggest that down-regulated BTG1 expression might promote gastric carcinogenesis partially due to its promoter methylation. BTG1 overexpression might reverse the aggressive phenotypes. PMID:26050197
9. Reduced BTG1 expression is associated with increased nasopharyngeal cancer severity, suggesting it is a negative regulator of the cancer and can serve as a prognostic indicator. Reduced BTG1 expression is possibly associated with tumour metastasis. PMID:24985971
10. Our results indicate that altered BTG1 expression might affect hepatocarcinogenesis and may represent a novel biomarker for HCC carcinogenesis and progression. PMID:25405901
11. Data indicate that microRNA-19a regulates prostate cancer cells by directly targeting B cell translocation gene-1 protein BTG1. PMID:25936765
12. Altered expression of BTG1 is a potential biomarker for carcinogenesis and progression of gastric cancer, particularly for proximal nondiffuse and diffuse GC. PMID:25487193
13. Results show that reduced BTG1 expression is associated with increased disease severity, suggesting it as negative regulator of thyroid cancer. PMID:25017022
14. Down-regulation of BTG1 by miR-454-3p renders tumor cells sensitive to radiation. PMID:25115181
15. BTG1 protein levels were significantly reduced in hepatocellular cancer and were associated with lymph node metastasis, clinical stage, cell differentiation, and prognosis. PMID:25173640
16. Bcell translocation 1 gene inhibits cellular metastasisassociated behavior in breast cancer. PMID:24714932
17. Reduced BTG1 expression is associated with increased disease severity, suggesting it is a negative regulator of esophageal cancer PMID:24969561
18. BTG1 deletions might play a role in leukemogenesis of B-cell precursor acute lymphoblastic leukemia as well as of BCR-ABL1-positive mixed-phenotype acute leukemia and chronic myeloid leukemia in B-lineage blast crisis (B-lineage). PMID:24998463
19. BTG1 may play important roles as a negative regulator to breast cancer cell. PMID:24272202
20. BTG1 expression decreased in nonsmall cell lung cancer and correlated significantly with lymph node metastasis; clinical stage; histological grade; poor overall survival PMID:24264312
21. Altered BTG1 expression might play a role in the pathogenesis. PMID:24084718
22. These results indicate that BTG1 may be used as a novel therapeutic target for human breast cancer treatment. PMID:23982470
23. BTG1 deletions are not associated with down syndrome acute lymphoblastic leukemia PMID:22868968
24. BTG1 loss is a novel finding in acute lymphoblastic leukemia in children with down syndrome PMID:22072402
25. BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. PMID:20354172
26. Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin-proteasome system. the C-terminal regions are necessary and sufficient to control the stabilities of BTG1, BTG2, Tob, and Tob2 proteins. PMID:12135500
27. FoxO3a controls expression of BTG1 and subsequent regulation of protein arginine methyl transferase activity. PMID:14734530
28. BTG1 may play an important role in the process of angiogenesis PMID:15033446
29. BTG1 is a novel important coactivator involved in the regulation of myoblast differentiation. PMID:15674337
30. five genes (TNFSF10/TRAIL, IL1RN, IFI27, GZMB, and CCR5) were upregulated and three genes (CLK1, TNFAIP3 and BTG1) were downregulated in at least three out of four subpopulations during acute GVHD. PMID:18814951
31. These findings support the hypothesis that BTG1 polymorphisms may influence genetic predisposition for MS, especially in relapse-onset MS patients. PMID:19515430

Show More

Hide All

HGNC: 1130

UNIGENE: Hs.255935

KEGG: hsa:694

STRING: 9606.ENSP00000256015

OMIM: 109580